Organ Regeneration by Application of Biomaterials and Stem Cells Technology Tools

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Biopharmaceuticals".

Deadline for manuscript submissions: 12 July 2025 | Viewed by 646

Special Issue Editor


E-Mail Website
Guest Editor
Department of Cardiac Thoracic and Vascular Sciences and Public Health, Italy LifeLab Torre della Ricerca, 5 piano sud , Corso Stati Uniti 4, 35127 Padua, Italy
Interests: Human induced pluripotent stem cells; disease modeling; organ regeneration; drug discovery; toxicity screening
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

There are various research areas in which stem cell technology could make substantial contributions to the development and implementation of stem cell-based models for toxicity testing. Increased use of human in vitro models of toxicity could reduce the use of animals in safety and risk assessment studies and offers the potential to dramatically enhance our understanding of the molecular basis of toxicity, leading to improved human models and assays for predicting biological responses to drugs and environmental hazards. Biomaterials are substances, applied in various fields of medicine that are used to stay in constant contact with body tissues. The most frequently practiced example is tooth filling where most people first encounter biomaterials. The other most delicate examples like cardiac repair with heart valves, and joint replacements. Various categories of biomaterials have now been successfully developed and used for more than a generation. First-generation biomaterials largely depended on being inert, or relatively inert, with minimal tissue response. Despite the wide application and its usefulness in human health, nonspecific host immune response is always a challenge to encounter which are prone to infections. Modern biomaterials science provides a large array of biomaterial designs and surface modifications that modulate the host–material interactions to prevent an aggressive foreign-body response and at the same time avoid bacterial colonization. Furthermore, the use of biological motives in the new generations of biomaterials may elicit a specific immune response. Our special issue will cover the following main aspects of the biomaterial application and characterization and proposition of new biomaterial, which could be animal and synthetic origin with less host-tissue immune responses.

  • New methods and protocols to develop to characterize the animal, human and synthetic origin tissues
  • Interaction of cells/stem cells and materials at the microenvironment
  • Materials as model systems for stem cell growth and modulation into tissue-specific cells
  • (Nano)materials and (nano)systems for therapeutic delivery
  • Biomimetic materials, including biologically inspired cell-inspired synthetic tools

Dr. Saima Imran
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • stem cells
  • biomaterial
  • biocompatibility
  • regenerative medicine
  • tissue engineering
  • acellular matrix
  • decellularization
  • disease modeling

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

21 pages, 7137 KiB  
Article
Comparison of the Efficacy of Two Routes of Administration of Human Amniotic Epithelial Cells in Cell Therapy of Acute Hepatic Insufficiency
by Patrycja Wieczorek, Piotr Czekaj, Mateusz Król, Edyta Bogunia, Mateusz Hermyt, Emanuel Kolanko, Jakub Toczek, Aleksandra Skubis-Sikora, Aniela Grajoszek and Rafał Stojko
Pharmaceuticals 2024, 17(4), 476; https://doi.org/10.3390/ph17040476 - 08 Apr 2024
Viewed by 216
Abstract
The route of administration of implanted cells may affect the outcome of cell therapy by directing cell migration to the damaged site. However, the question of the relationship between the route of administration, the efficacy of colonisation of a given organ, and the [...] Read more.
The route of administration of implanted cells may affect the outcome of cell therapy by directing cell migration to the damaged site. However, the question of the relationship between the route of administration, the efficacy of colonisation of a given organ, and the efficacy of cell therapy has not been resolved. The aim of the study was to localise transplanted intravenously and intraperitoneally human amniotic epithelial cells (hAECs) in the tissues of mice, both healthy and injured, in an animal experimental model of acute liver failure (ALF). Mice intoxicated with D-Galactosamine (D-GalN) at a dose of 150 mg/100 g body weight received D-GalN alone or with a single dose of hAECs administered by different routes. Subsequently, at 6, 24, and 72 h after D-GaIN administration and at 3, 21, and 69 h after hAEC administration, lungs, spleen, liver, and blood were collected from recipient mice. The degree of liver damage and regeneration was assessed based on biochemical blood parameters, histopathological evaluation (H&E staining), and immunodetection of proliferating (Ki67+) and apoptotic (Casp+) cells. The biodistribution of the administered cells was based on immunohistochemistry and the identification of human DNA. It has been shown that after intravenous administration, in both healthy and intoxicated mice, most of the transplanted hAECs were found in the lungs, while after intraperitoneal administration, they were found in the liver. We concluded that a large number of hAECs implanted in the lungs following intravenous administration can exert a therapeutic effect on the damaged liver, while the regenerative effect of intraperitoneally injected hAECs on the liver was very limited due to the relatively lower efficiency of cell engraftment. Full article
Show Figures

Figure 1

Back to TopTop